| Followers | 35 |
| Posts | 2799 |
| Boards Moderated | 0 |
| Alias Born | 10/28/2013 |
Tuesday, July 08, 2025 11:31:18 PM
It has never made any sense that there isn't a major following for Agenus here on iHub. Hooya is a joke. Bot and Bal really are incredible and the phase 2 data is incredible. There should be all kinds of chatter about a rigged FDA etc... as you always hear in these small cap biotech message boards... but this time, it's real. This drug combo is absolutely spectacular and it did not get accelerated approval for 1 reason; because it would disrupt the entire oncology space. It would interfere with the guaranteed returns for the ultra-rich who can't be bothered to study up and pick their own stocks, but instead hand their money to ruthless crooks. Just take a look at the Hooya page for Agenus and you will see just the tip of the iceberg.
Recent AGEN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:35:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:34:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:02 PM
- アジーナス、BOT+BALアクセスプログラムの独占的グローバルパートナーにBAP Pharmaを指名 • Business Wire • 04/22/2026 03:56:00 PM
- Agenus désigne BAP Pharma comme partenaire mondial exclusif pour les programmes d’accès à la combinaison BOT+BAL • Business Wire • 04/22/2026 12:55:00 AM
- Agenus ernennt BAP Pharma zum exklusiven globalen Partner für die BOT+BAL-Zugangsprogramme • Business Wire • 04/22/2026 12:55:00 AM
- Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 • Business Wire • 04/21/2026 02:00:00 PM
- Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs • Business Wire • 04/21/2026 12:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/20/2026 09:21:47 PM
- Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer • Business Wire • 04/17/2026 08:43:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 08:15:10 PM
- Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 • Business Wire • 04/03/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:29 PM
- アジーナス、MSSまたはpMMRの転移性大腸がんを対象としたBOT+BAL免疫療法併用のグローバル第3相BATTMAN試験で初の患者登録を発表 • Business Wire • 04/02/2026 04:31:00 AM
- Agenus annonce le recrutement du premier patient dans l’essai mondial de phase III BATTMAN portant sur l’association immunothérapeutique BOT+BAL dans le cadre du cancer colorectal métastatique MSS ou pMMR • Business Wire • 04/02/2026 04:27:00 AM
- Agenus gibt die Aufnahme des ersten Patienten in die globale Phase-3-Studie BATTMAN bekannt, in der die Immuntherapie-Kombination aus BOT und BAL bei metastasiertem kolorektalem Karzinom der MSS- oder pMMR-Gruppe untersucht wird • Business Wire • 04/02/2026 03:50:00 AM
- Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer • Business Wire • 04/01/2026 11:30:00 AM
- Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access • Business Wire • 03/26/2026 08:52:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:24:51 PM
